Kiadis And Sanofi Sign Natural Killer Cell Therapy Pact
Big Pharma Boost For Dutch Biotech
Sanofi is paying €17.5m upfront to combine a preclinical NK cell product with its anti-CD38 antibody Sarclisa and develop a multiple myeloma drug that potentially may prove more effective than J&J's Darzalex, Kiadis's CEO tells Scrip.
